Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer-Reference-Cited by-同舟云学术

Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer

Published:2014-07-08 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Akl Elie A¹,Kahale Lara A²,Barba Maddalena³,Neumann Ignacio⁴,Labedi Nawman⁵,Terrenato Irene⁶,Sperati Francesca⁶,Muti Paola⁷,Schünemann Holger⁸

Affiliation:

1. American University of Beirut; Department of Internal Medicine; Riad El Solh St Beirut Lebanon

2. American University of Beirut; Faculty of Medicine; Beirut Lebanon

3. Regina Elena National Cancer Institute; Division of Medical Oncology B - Scientific Direction; Via Elio Chianesi 53 Rome Italy 00144

4. Faculty of Medicine, Pontificia Universidad Católica de Chile; Department of Internal Medicine, Evidence Based Health Care Program; Lira 44, Santiago Santiago Región metropolitana Chile

5. State University of New York at Buffalo; Department of Medicine; ECMC CC-142 462 Grider Street Buffalo NY USA 14215

6. Regina Elena National Cancer Institute; Biostatistics-Scientific Direction; Via Elio Chianesi 53 Rome Italy 00144

7. National Cancer Institute Regina Elena; Department of Epidemiology; Via Elio Chianesi 53 Rome Italy 00144

8. McMaster University; Departments of Clinical Epidemiology and Biostatistics and of Medicine; 1280 Main Street West Hamilton ON Canada L8N 4K1

Publisher

Wiley

Subject

Pharmacology (medical)

Reference88 articles.

1. Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients;Cesarone;Circulation,2003

2. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period;Deitcher;Clinical & Applied Thrombosis/Hemostasis,2006

3. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer;Hull;American Journal of Medicine,2006

4. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer;Lee;New England Journal of Medicine,2003

5. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism;Lee;Journal of Clinical Oncology,2005

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venous thromboembolism treatment in patients with cancer: reflections on an evolving landscape;Bleeding, Thrombosis and Vascular Biology;2024-02-29

2. Moderne Antikoagulation mit FXa-Inhibitoren in der Onkologie: Ist die gastrointestinale Blutungsrate (mit)-entscheidend?;Zeitschrift für Gastroenterologie;2022-07-25

3. IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism;Japanese Journal of Clinical Oncology;2022-06-29

4. Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism;Trends in Cardiovascular Medicine;2022-02

5. Multiple myeloma and deep vein thrombosis/pulmonary thromboembolism - incidence and risk factors;Medical review;2022